Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services National Institutes of Health
 AGENCY: National Institutes of Health, HHS.
 ACTION: Notice.
 SUMMARY: The National Human Genome Research Institute (NHGRI), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive, Sublicensable Patent License to consolidate co-owned rights to the inventions and the Patents and Patent Applications listed in the Supplementary Information section of this notice to The Progeria Research Foundation (“PRF”), having a place of business in 200 Lake Street, Unit 102, Peabody, MA 01960.
 DATES: Only written comments and/or applications for a license that are received by the NHGRI Office of Technology Transfer Office on or before July 27, 2021 will be considered.
 ADDRESSES: Requests for a copy of the patent application(s), inquiries, and comments relating to the contemplated license should be directed to: Eggerton Campbell, License and Patent Manager, NHGRI Technology Transfer Office, Telephone: 301-402-1648; email: 
                        *eggerton.campbell@nih.gov.*


SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement: Country
Title
Application No.
Patent No.United States
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-US-01
61/568,590WIPO
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-PCT-03
PCT/US12/068609
                             WO 2013/086444United Kingdom
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-GB-12
12806796.4
2788488United States
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-US-02
13/708,709
9,326,992United States
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-US-06
15/084,255
9,833,468United States
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-US-07
15/727,483 CON
10,398,721Europe
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-EP-04
12806796.4
2788488Japan
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-JP-15
2019-109410France
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-FR-11
12806796.4
2788488Germany
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-DE-10
12806796.4
2788488Ireland
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-IE-13
12806796.4
2788488Japan
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-JP-05
2014-546152
6132849Japan
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-JP-08
2017-41744Netherlands
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-NL-14
12806796.4
2788488Switzerland
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-0-CH-09
12806796.4
2788488United States
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-US-01
62/330,027WIPO
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-PCT-02
PCT/US17/30174
                             WO 2017/190041( print page 36564)United States
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-US-16
16/096,524 (371-national phase)
10,822,608United States
Oligonucleotide Analogues Targeting Human LMNA
17/024,100Australia
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-AU-03
2017258642Brazil
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-BR-04
BR1120180722790Canada
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-CA-05
3,022,303China
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-CN-06
201780040785.7Colombia
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-CO-07
NC2018/0012783Eurasia
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-EA-08
201892467Europe
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-EP-09
17735676.3Hong Kong
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-HK-17
19126894.5India
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-IN-10
201847043433Japan
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-JP-11
2019-508165Korea (South)
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-KR-12
10-2018-7034615Mexico
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-MX-13
MX/A/2018/013157New Zealand
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-NZ-14
747685Singapore
Oligonucleotide Analogues Targeting Human LMNA NIH E-044-2013-1-SG-15
11201809468X
 The patent rights in these inventions have been assigned to the Government of the United States of America, the University of Maryland, Sarepta Therapeutics, Inc, and the Progeria Research Foundation (PRF), co-owners of said rights, for commercial development and marketing. The rights to be granted by NHGRI are controlled by NHGRI by virtue of co-ownership and a license received to the listed intellectual property. The prospective patent license will be for the purpose of consolidating the patent rights to PRF. Consolidation of these co-owned rights is intended to expedite development of the invention, consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C. 200-212. The prospective patent license will be worldwide, exclusive, may be limited to those fields of use commensurate in scope with the patent rights, and will be sublicensable. The subject technology pertains to modified oligonucleotides (called phosphorodiamidate morpholino oligonucleotides or PMOs) targeted to pre-mRNA of human LMNA Lamin A gene. These PMOs can be used to correct aberrant splicing of LMNA gene known to be involved in Hutchinson-Gilford Progeria Syndrome (HGPS), and could be used in treating this ultra-rare disease and related laminopathies. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective Exclusive Patent License will be royalty bearing and may be granted unless, within fifteen (15) days from the date of this published notice, the NHGRI Technology Transfer Office receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. Complete applications for a license that are timely filed in response to this notice will be treated as objections to this to the grant of the contemplated exclusive patent license. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available. License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the 
                    *Freedom of Information Act,*5 U.S.C. 552. Dated: June 29, 2021. Claire T. Driscoll, Director, Technology Transfer Office, National Human Genome Research Institute, National Institutes of Health.


[FR Doc. 2021-14702 Filed 7-9-21; 8:45 am] BILLING CODE 4140-01-P